



Estelle® Study Results Published in Leading Peer-Reviewed Medical Journal

- Publication of an article on Estelle® endocrine and metabolic parameters in prestigious Contraception Journal
- Article concludes on limited impact of Estelle® compared to Ethinylestradiol-based combined oral contraceptives
- Estelle® filing on going in the U.S., Europe and Canada, with expected marketing authorization in H12021

Liege, Belgium, 9 February 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the publication of a scientific paper entitled "*Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone*" in Contraception Journal, one of the most prestigious peer-reviewed journals in the field. A link to this publication can be accessed [here](#).

This scientific paper highlights the limited effects of a new combined oral contraceptive (COC) containing Estetrol (E4) and Drospirenone (DRSP) - namely the Estelle® product candidate developed by Mithra - on endocrine and metabolic parameters in a comparative study with the two frequently used COC's based on Ethinylestradiol (EE): one combined with Levonorgestrel and the other with Drospirenone, to validate changes related to the estrogen source. Currently, about 97% of marketed combined oral contraceptives are based on the synthetic estrogen Ethinylestradiol.

The results of this study confirm previous observations that Estelle® has a minimal impact on liver proteins, lipid profile, carbohydrate metabolism, cortisol and gonadotropins. The effects on liver proteins, triglycerides and endocrine parameters such as cortisol were less pronounced compared to Ethinylestradiol-based products. This profile is supported by the unique mode of action of Estetrol, which is a native estrogen produced by the foetus during pregnancy and acting selectively in tissues.

Graham Dixon, CSO Mithra Women's Health, commented: *"We are very pleased that the positive results from this comparative study on our product candidate Estelle® have been published in one of the most prestigious and well-respected scientific journals, that serves as a reference in the medical sphere. This article highlights that Estelle® could really offer women a promising new contraceptive solution, with a number of advantages over current COCs pills. We look forward to the feedback of regulatory agencies in the United States, Europe and Canada, with marketing authorization in the first half of this year."*

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 - press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)